This module uses fundamental data of NextCure to approximate its Piotroski F score. NextCure F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of NextCure. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about NextCure financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out NextCure Altman Z Score, NextCure Correlation, NextCure Valuation, as well as analyze NextCure Alpha and Beta and NextCure Hype Analysis.
At present, NextCure's Debt To Equity is projected to increase slightly based on the last few years of reporting. The current year's Interest Debt Per Share is expected to grow to 0.25, whereas Short and Long Term Debt Total is forecasted to decline to about 4.4 M. At present, NextCure's Book Value Per Share is projected to increase based on the last few years of reporting. The current year's PB Ratio is expected to grow to 0.29, whereas Free Cash Flow Yield is projected to grow to (1.61).
At this time, it appears that NextCure's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to NextCure is to make sure NextCure is not a subject of accounting manipulations and runs a healthy internal audit department. So, if NextCure's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if NextCure's financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between NextCure's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards NextCure in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
4.87
At present, NextCure's Book Value Per Share is projected to increase based on the last few years of reporting.
NextCure Current Valuation Drivers
We derive many important indicators used in calculating different scores of NextCure from analyzing NextCure's financial statements. These drivers represent accounts that assess NextCure's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of NextCure's important valuation drivers and their relationship over time.
The Macroaxis Fundamental Analysis modules help investors analyze NextCure's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NextCure using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NextCure based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether NextCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NextCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nextcure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nextcure Stock:
For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.19)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.31)
Return On Equity
(0.55)
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.